Nicotinamide Mononucleotide (Nmn) For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Nicotinamide mononucleotide (NMN) is a nucleoside ribomonophosphate that serves as a key intermediate in the biosynthesis of nicotinamide adenine dinucleotide (NAD+)[1]. NAD+ is an essential coenzyme for numerous enzymatic reactions involved in cellular metabolism, DNA repair, and stress responses. NMN supplementation has emerged as a promising strategy to restore NAD+ levels in aging and neurodegenerative diseases.
NMN is synthesized in the body through multiple pathways:
| Pathway | Starting Material | Enzyme | Location |
|---|---|---|---|
| Salvage pathway | Nicotinamide | NAMPT | Cytosol |
| Preiss-Handler pathway | Nicotinic acid | NAPRT | Cytosol |
| de novo pathway | Tryptophan | Multiple | Mitochondria |
NMN is directly converted to NAD+ by the enzyme NMN adenylyltransferase (NMNAT):
NMN + ATP → NAD+ + PPi (2 molecules)
This reaction occurs in multiple tissues, including the brain, making NMN an efficient NAD+ precursor.
NMN increases NAD+ levels, which in turn activates sirtuin enzymes:
| Sirtuin | Function | Brain Relevance |
|---|---|---|
| SIRT1 | Deacetylase | Neuroprotection, circadian rhythm |
| SIRT3 | Mitochondrial | Mitochondrial function |
| SIRT6 | Genome stability | DNA repair |
| Trial | Phase | Dose | Duration | Outcome |
|---|---|---|---|---|
| Various | I | 100-500mg | 2-4 weeks | Safe, well-tolerated |
| Preclinical | N/A | 100-300mg/kg | Months | Improved cognition |
Key Findings:
| Study | Model | Outcome |
|---|---|---|
| NMN in MPTP mice | Preclinical | Protected dopaminergic neurons |
| NMN + exercise | Preclinical | Additive benefits |
| NMN + CoQ10 | Preclinical | Synergistic neuroprotection |
| Parameter | Value |
|---|---|
| Oral bioavailability | ~40-60% |
| Tmax (oral) | 2-3 hours |
| Half-life | ~2-3 hours |
NMN crosses the blood-brain barrier through specific transporters:
| Population | Dose | Frequency |
|---|---|---|
| Human studies | 100-500mg | Daily |
| Preclinical | 100-300mg/kg | Daily |
The study of Nicotinamide Mononucleotide (Nmn) For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
| Combination | Potential Benefit | Evidence Level |
|---|---|---|
| NMN + NR | Complementary pathways | Preclinical |
| NMN + Resveratrol | SIRT1 activation | Preclinical |
| NMN + PARP inhibitors | Preserved NAD+ | Theoretical |
| Agent | Interaction | Potential |
|---|---|---|
| GLP-1 agonists | Complementary mechanisms | Promising |
| Spermidine | Autophagy enhancement | Preclinical |
| Lithium | GSK3β inhibition | Exploratory |
| Trial | Phase | Condition | Primary Outcome |
|---|---|---|---|
| Various | I | Healthy aging | Safety, PK |
| Various | II | MCI | Cognitive function |
| Various | II | Parkinson's | Motor function |
Key biomarkers being tracked in NMN trials:
Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Nat Cell Biol. 2014. ↩︎